Journal of Clinical Oncology, Vol 10, 696-705, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Factors predicting treatment responsiveness and prognosis in node- negative breast cancer. The International (Ludwig) Breast Cancer Study Group

AM Neville, R Bettelheim, RD Gelber, J Save-Soderbergh, BW Davis, R Reed, J Torhorst, R Golouh, HF Peterson and KN Price
International Breast Cancer Study Group, Bern, Switzerland.

PURPOSE: An international trial (formerly Ludwig Trial V) has been conducted in 1,275 subjects to ascertain if perioperative chemotherapy is beneficial for node-negative breast cancer patients and to identify subgroups of patients who benefit from this therapy. PATIENTS AND METHODS: Node-negative breast cancer patients were randomized to receive either one cycle of perioperative chemotherapy or no adjuvant treatment. A detailed pathology review was conducted in 1,203 of the 1,275 patients enrolled. Stepwise Cox regression analysis was used to search for factors either predicting chemotherapeutic responsiveness and/or influencing disease-free survival (DFS). RESULTS: As expected, primary tumor size, grade, and the presence of peritumoral vascular invasion are the most important prognostic factors. Perioperative chemotherapy provides a DFS advantage at 5 years of median follow-up and such treatment is more effective for estrogen receptor-negative than for estrogen receptor-positive tumors, for histologic grade 2 and 3 than for grade 1 tumors, and for patients in whom no axillary lymph node metastases were found even after serial sectioning and review by the Central Pathology Laboratory. CONCLUSION: Hormone receptor status and tumor grade are important factors for predicting responsiveness to perioperative chemotherapy in node-negative breast cancer.

This article has been cited by other articles:

				J. S. Jeruss, E. A. Mittendorf, S. L. Tucker, A. M. Gonzalez-Angulo, T. A. Buchholz, A. A. Sahin, J. N. Cormier, A. U. Buzdar, G. N. Hortobagyi, and K. K. Hunt Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant Therapy J. Clin. Oncol., January 10, 2008; 26(2): 246 - 252. [Abstract] [Full Text] [PDF]

				M. Colleoni, N. Rotmensz, P. Maisonneuve, A. Sonzogni, G. Pruneri, C. Casadio, A. Luini, P. Veronesi, M. Intra, V. Galimberti, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer Ann. Onc., October 1, 2007; 18(10): 1632 - 1640. [Abstract] [Full Text] [PDF]

				A. J. Evans, S. E. Pinder, J. J. James, I. O. Ellis, and E. Cornford Is mammographic spiculation an independent, good prognostic factor in screening-detected invasive breast cancer? Am. J. Roentgenol., November 1, 2006; 187(5): 1377 - 1380. [Abstract] [Full Text] [PDF]

				P J Westenend, C J C Meurs, and R A M Damhuis Tumour size and vascular invasion predict distant metastasis in stage I breast cancer. Grade distinguishes early and late metastasis J. Clin. Pathol., February 1, 2005; 58(2): 196 - 201. [Abstract] [Full Text] [PDF]

				M. Colleoni, N. Rotmensz, G. Peruzzotti, P. Maisonneuve, G. Viale, G. Renne, C. Casadio, P. Veronesi, M. Intra, R. Torrisi, et al. Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies Ann. Onc., November 1, 2004; 15(11): 1633 - 1639. [Abstract] [Full Text] [PDF]

				M. Cianfrocca and L. J. Goldstein Prognostic and Predictive Factors in Early-Stage Breast Cancer Oncologist, November 1, 2004; 9(6): 606 - 616. [Abstract] [Full Text] [PDF]

				M. Colleoni, N. Rotmensz, C. Robertson, L. Orlando, G. Viale, G. Renne, A. Luini, P. Veronesi, M. Intra, R. Orecchia, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation Ann. Onc., February 20, 2002; 13(2): 273 - 279. [Abstract] [Full Text] [PDF]

				M. Colleoni, S. Gelber, A. S. Coates, M. Castiglione-Gertsch, R. D. Gelber, K. Price, C.-M. Rudenstam, J. Lindtner, J. Collins, B. Thurlimann, et al. Influence of Endocrine-Related Factors on Response to Perioperative Chemotherapy for Patients With Node-Negative Breast Cancer J. Clin. Oncol., November 1, 2001; 19(21): 4141 - 4149. [Abstract] [Full Text] [PDF]

				H Denley, S E Pinder, C W Elston, A H S Lee, and I O Ellis Preoperative assessment of prognostic factors in breast cancer J. Clin. Pathol., January 1, 2001; 54(1): 20 - 24. [Abstract] [Full Text] [PDF]

				PREDICTING PROGNOSIS OF NODE-NEGATIVE BREAST CANCER Journal Watch (General), June 19, 1992; 1992(619): 5 - 5. [Full Text]